152 related articles for article (PubMed ID: 16574492)
1. Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein.
Dambach MJ; Trecki J; Martin N; Markovitz NS
Mol Ther; 2006 May; 13(5):891-8. PubMed ID: 16574492
[TBL] [Abstract][Full Text] [Related]
2. A virus with a mutation in the ICP4-binding site in the L/ST promoter of herpes simplex virus type 1, but not a virus with a mutation in open reading frame P, exhibits cell-type-specific expression of gamma(1)34.5 transcripts and latency-associated transcripts.
Lee LY; Schaffer PA
J Virol; 1998 May; 72(5):4250-64. PubMed ID: 9557715
[TBL] [Abstract][Full Text] [Related]
3. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
[TBL] [Abstract][Full Text] [Related]
4. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells.
Chung RY; Saeki Y; Chiocca EA
J Virol; 1999 Sep; 73(9):7556-64. PubMed ID: 10438845
[TBL] [Abstract][Full Text] [Related]
5. Up to four distinct polypeptides are produced from the γ34.5 open reading frame of herpes simplex virus 2.
Korom M; Davis KL; Morrison LA
J Virol; 2014 Oct; 88(19):11284-96. PubMed ID: 25031346
[TBL] [Abstract][Full Text] [Related]
6. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha.
Cassady KA; Gross M; Roizman B
J Virol; 1998 Sep; 72(9):7005-11. PubMed ID: 9696792
[TBL] [Abstract][Full Text] [Related]
7. Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.
Kanai R; Zaupa C; Sgubin D; Antoszczyk SJ; Martuza RL; Wakimoto H; Rabkin SD
J Virol; 2012 Apr; 86(8):4420-31. PubMed ID: 22345479
[TBL] [Abstract][Full Text] [Related]
8. Replication-Competent Controlled Herpes Simplex Virus.
Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
[TBL] [Abstract][Full Text] [Related]
9. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
10. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
11. Point mutations in exon I of the herpes simplex virus putative terminase subunit, UL15, indicate that the most conserved residues are essential for cleavage and packaging.
Przech AJ; Yu D; Weller SK
J Virol; 2003 Sep; 77(17):9613-21. PubMed ID: 12915573
[TBL] [Abstract][Full Text] [Related]
12. The herpes simplex virus type 1 UL3 transcript starts within the UL3 open reading frame and encodes a 224-amino-acid protein.
Markovitz NS
J Virol; 2007 Oct; 81(19):10524-31. PubMed ID: 17626086
[TBL] [Abstract][Full Text] [Related]
13. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
14. Neurovirulent factor ICP34.5 uniquely expressed in the herpes simplex virus type 1 Delta gamma 1 34.5 mutant 1716.
Holman HA; MacLean AR
J Neurovirol; 2008 Jan; 14(1):28-40. PubMed ID: 18300073
[TBL] [Abstract][Full Text] [Related]
15. Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter.
Longo SL; Griffith C; Glass A; Shillitoe EJ; Post DE
Cancer Gene Ther; 2011 Feb; 18(2):123-34. PubMed ID: 20930860
[TBL] [Abstract][Full Text] [Related]
16. Ultrastructural analysis of ICP34.5- herpes simplex virus 1 replication in mouse brain cells in vivo.
Mehta H; Muller J; Markovitz NS
J Virol; 2010 Nov; 84(21):10982-90. PubMed ID: 20702618
[TBL] [Abstract][Full Text] [Related]
17. Role of Herpes Simplex Virus 1 γ34.5 in the Regulation of IRF3 Signaling.
Manivanh R; Mehrbach J; Knipe DM; Leib DA
J Virol; 2017 Dec; 91(23):. PubMed ID: 28904192
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells.
Fasullo M; Burch AD; Britton A
Cell Cycle; 2009 Jul; 8(14):2194-7. PubMed ID: 19502787
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
20. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
